search
Back to results

Testosterone and Long Pulse Stimulation After SCI

Primary Purpose

Spinal Cord Injury

Status
Active
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Testosterone and LPWS
Testosterone and standard NMES
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injury focused on measuring Electric Stimulation, Spinal Cord Injuries, Muscle Denervation, carbohydrate metabolism, Lipids metabolism, Basal Metabolic Rate, Muscle Proteins, Mitochondria, Muscle, RNA, Rehabilitation

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Traumatic motor complete SCI and level of injury of T10 and below
  • Only participants with lower motor neuron (LMN) denervation as determined by EMG testing
  • Participants must also have an absence of reflexes, denervation of both knee extensor muscles
  • Tolerance to LPWS paradigm
  • Both knee extensors will also have to be unresponsive (i.e., no observed tetanic contraction or twitches) to standard electrical stimulation procedures (stimulation frequency: 30 Hz; pulse duration:450 s and amplitude of the current:200 mA)
  • All participants will undergo International Standards for Neurological Classification of SCI (ISNCSCI) examination for neurological level and function and only those with American Spinal Injury Classification (AIS A and B; i.e. motor deficit below the level of injury)

Exclusion Criteria:

  • Diagnosis of neurological injury other than SCI
  • Pre-existing medical conditions will be excluded (cardiovascular disease, uncontrolled type II DM and those on insulin requirements) or other concurrent medical conditions judged to be contraindicated by the site physician.
  • Hematocrit above 50% and severe urinary tract infection or symptoms
  • Those with hyper-physiological testosterone level above 800 ng/dl
  • Those who will fail to tolerate the LPWS paradigm
  • Progressive condition that would be expected to result in changing neurological status
  • Lower extremity fracture around the knee joint (distal femur or proximal tibia) within the last 2 years from enrollment in the study
  • Knee BMD < 0.60 gm/cm2
  • Total hip BMD T-scores < -3.5
  • Untreatable severe spasticity judged to be contraindicated by the site Physician
  • Untreated or uncontrolled hypertension (systolic blood pressure >140 mmHg; diastolic blood pressure >90 mmHg)
  • Pressure ulcer of the trunk, pelvic area, or lower extremities of grade 3 or more
  • Psychopathology documentation in the medical record or history that may conflict with study objectives

Sites / Locations

  • Hunter Holmes McGuire VA Medical Center, Richmond, VA

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Testosterone and LPWS

Testosterone and standard NMES

Arm Description

Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.

Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.

Outcomes

Primary Outcome Measures

Muscle Size Change
Magnetic resonance imaging (MRI): The skeletal muscle area will be measured at baseline, 6 months (mid-intervention) and 1 year after training (post-intervention).

Secondary Outcome Measures

Basal Metabolic Rate
Using indirect canopy after overnight 10-12 hours fast.
Mitochondrial enzymatic activities
Performing a simple muscle biopsy and them muscle samples will be assayed to measure mitochondrial citrate synthase and other complexes.

Full Information

First Posted
November 13, 2017
Last Updated
August 11, 2023
Sponsor
VA Office of Research and Development
Collaborators
Hunter Holmes McGuire VA Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03345576
Brief Title
Testosterone and Long Pulse Stimulation After SCI
Official Title
Testosterone and Long Pulse Width Stimulation for Denervated Muscles After Spinal Cord Injury
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 1, 2018 (Actual)
Primary Completion Date
June 30, 2023 (Actual)
Study Completion Date
November 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
Collaborators
Hunter Holmes McGuire VA Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Denervation following spinal cord injury (SCI) limits beneficial application of neuromuscular electrical stimulation (NMES). SCI with denervation results in extensive muscle atrophy that is accompanied with several cardio-metabolic health risks. The current proposal provides a novel intervention by examining the effects of long pulse width stimulation (LPWS) and testosterone replacement therapy (TRT) on restoring muscle size and leg lean mass after denervation in persons with SCI. This intervention will be rewarding for Veterans and Civilians with SCI who do not benefit from exercising their lower extremity muscles because denervation has limited the response to standard surface NMES. The investigators will study the biochemical mechanisms that contribute to changes in muscle size following this novel training. Combing both pharmaceutical and physical-therapeutic interventions will optimize restoration of muscle size after SCI.
Detailed Description
The long-term goal is to develop a rehabilitation strategy to mitigate the deleterious changes in muscle size and lower leg lean mass in persons with denervation following spinal cord injury (SCI). Currently, there is no available rehabilitation intervention following lower motor neuron (LMN) denervation. More than 46,000 Veterans are affected with SCI and may experience profound skeletal muscle atrophy and loss of lean mass and about 20-25% experience LMN denervation. Skeletal muscle cross-sectional area is 6 times smaller following LMN denervation compared to the innervated muscles. Denervation atrophy may be accompanied by several SCI health-related consequences. Twelve weeks of twice weekly of surface neuromuscular electrical stimulation (NMES) resistance training (RT) can elicit more than a 35% increase in skeletal muscle size, decreased ectopic adipose tissue accumulation, increased insulin sensitivity after SCI. Moreover, the applicant's CDA-2 preliminary findings showed that 16 weeks of NMES-RT and testosterone replacement therapy (TRT) increased leg lean mass by 1.5 kg with no changes in the TRT group only. This was accompanied by an increase in the basal metabolic rate (BMR) of 218 kcal/day in the NMES-RT+TRT with no changes in the TRT group. During the course of recruitment for the study, 20% of individuals with SCI were excluded and could not benefit from exercising their lower extremity muscles, presumably because of LMN denervation. Long pulse width stimulation (LPWS; 120-150 ms) has the potential to stimulate denervated muscles and to restore muscle size in people with SCI. The previous paradigm has focused on daily activation of the denervated muscles without applying progressive loading similar to RT. Daily training is not a clinically feasible approach in persons with SCI. Moreover, previous trials did not focus on enhancing the neuromuscular homeostasis by promoting the increase in lean mass independent of LMN denervation. Testosterone replacement therapy (TRT) has been shown to increase lean mass and basal metabolic rate in hypogonadal men with SCI. The investigators will determine if TRT+LPWS would increase skeletal muscle size, leg lean mass and improve overall metabolic health in SCI persons with LMN denervation. The investigators hypothesize that the one year TRT+LPWS protocol will upregulate protein synthesis pathways, down-regulate protein degradation pathways and increase overall mitochondrial health. Three specific aims will address these hypotheses. Aim 1 will assess the effects of TRT+LPWS compared to TRT+ standard neuromuscular electrical stimulation (NMES; as a control group) on the size of thigh skeletal muscle, intramuscular fat (IMF) and leg lean mass. Aim 2 will determine the association between the changes in skeletal muscle size, leg lean mass and the metabolic profile as determined by measuring BMR, serum lipids and carbohydrate profile. Aim 3 will investigate the cellular mechanisms responsible for evoking skeletal muscle hypertrophy following TRT+LPWS. This study is novel because it provides a feasible rehabilitation intervention by combining two approaches; which are likely to improve the quality of life in SCI persons with LMN denervation. If proven successful, the intervention will be easily translated into clinical practice for persons with SCI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injury
Keywords
Electric Stimulation, Spinal Cord Injuries, Muscle Denervation, carbohydrate metabolism, Lipids metabolism, Basal Metabolic Rate, Muscle Proteins, Mitochondria, Muscle, RNA, Rehabilitation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
Participant will be masked to the type of electrical stimulation (LPWS vs. standard NMES)
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Testosterone and LPWS
Arm Type
Experimental
Arm Description
Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
Arm Title
Testosterone and standard NMES
Arm Type
Sham Comparator
Arm Description
Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
Intervention Type
Device
Intervention Name(s)
Testosterone and LPWS
Other Intervention Name(s)
Testosterone and long pulse width stimulation
Intervention Description
Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
Intervention Type
Drug
Intervention Name(s)
Testosterone and standard NMES
Other Intervention Name(s)
Testosterone and neuromuscular electrical stimulation
Intervention Description
Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
Primary Outcome Measure Information:
Title
Muscle Size Change
Description
Magnetic resonance imaging (MRI): The skeletal muscle area will be measured at baseline, 6 months (mid-intervention) and 1 year after training (post-intervention).
Time Frame
Baseline, 6 months, and 1 year
Secondary Outcome Measure Information:
Title
Basal Metabolic Rate
Description
Using indirect canopy after overnight 10-12 hours fast.
Time Frame
1 year
Title
Mitochondrial enzymatic activities
Description
Performing a simple muscle biopsy and them muscle samples will be assayed to measure mitochondrial citrate synthase and other complexes.
Time Frame
1 year

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
Only men with SCI, women will not be included in the current study because administering testosterone replacement therapy (TRT) is neither appropriate nor safe.
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Traumatic motor complete SCI and level of injury of T10 and below Only participants with lower motor neuron (LMN) denervation as determined by EMG testing Participants must also have an absence of reflexes, denervation of both knee extensor muscles Tolerance to LPWS paradigm Both knee extensors will also have to be unresponsive (i.e., no observed tetanic contraction or twitches) to standard electrical stimulation procedures (stimulation frequency: 30 Hz; pulse duration:450 s and amplitude of the current:200 mA) All participants will undergo International Standards for Neurological Classification of SCI (ISNCSCI) examination for neurological level and function and only those with American Spinal Injury Classification (AIS A and B; i.e. motor deficit below the level of injury) Exclusion Criteria: Diagnosis of neurological injury other than SCI Pre-existing medical conditions will be excluded (cardiovascular disease, uncontrolled type II DM and those on insulin requirements) or other concurrent medical conditions judged to be contraindicated by the site physician. Hematocrit above 50% and severe urinary tract infection or symptoms Those with hyper-physiological testosterone level above 800 ng/dl Those who will fail to tolerate the LPWS paradigm Progressive condition that would be expected to result in changing neurological status Lower extremity fracture around the knee joint (distal femur or proximal tibia) within the last 2 years from enrollment in the study Knee BMD < 0.60 gm/cm2 Total hip BMD T-scores < -3.5 Untreatable severe spasticity judged to be contraindicated by the site Physician Untreated or uncontrolled hypertension (systolic blood pressure >140 mmHg; diastolic blood pressure >90 mmHg) Pressure ulcer of the trunk, pelvic area, or lower extremities of grade 3 or more Psychopathology documentation in the medical record or history that may conflict with study objectives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ashraf Gorgey, PhD PT
Organizational Affiliation
Hunter Holmes McGuire VA Medical Center, Richmond, VA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hunter Holmes McGuire VA Medical Center, Richmond, VA
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23249
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The target audiences for dissemination of the results from this study include the VHA and its practitioners, the national SCI/D Services Office, the general healthcare community, and the Veteran population. The investigators will share findings with the SCI community. The SCI/D Services and PVA publish a quarterly newsletter that is sent to SCI practitioners across the VA system. The investigators will inform the VA community of the impact of these findings. The investigators will report findings to the scientific community via the American Congress of Rehab Medicine, American College of Sports Medicine and American Spinal Cord Injury Association (ASIA). The investigators will publish reports in different scientific journals.
IPD Sharing Time Frame
Throughout the study and at the completion of the study.
Citations:
PubMed Identifier
36198461
Citation
Gorgey AS, Khalil RE, Alrubaye M, Gill R, Rivers J, Goetz LL, Cifu DX, Castillo T, Caruso D, Lavis TD, Lesnefsky EJ, Cardozo CC, Adler RA. Testosterone and long pulse width stimulation (TLPS) for denervated muscles after spinal cord injury: a study protocol of randomised clinical trial. BMJ Open. 2022 Oct 5;12(10):e064748. doi: 10.1136/bmjopen-2022-064748.
Results Reference
derived

Learn more about this trial

Testosterone and Long Pulse Stimulation After SCI

We'll reach out to this number within 24 hrs